ACE2 News and Research

RSS

Omicron infection linked to brain structure changes in men, study finds

Study reveals that men infected with the SARS-CoV-2 Omicron variant experience changes in brain structure, including reduced gray matter thickness and subcortical nuclear volume. These findings, based on MRI data and clinical symptoms, highlight the neurological impact of Omicron infection, contributing to our understanding of COVID-19's effects on the brain.

4 Dec 2023

Collaborative study focuses on understanding the strength of adhesion of COVID-19 variants

A recent groundbreaking study, published in Nature Nanotechnology, sheds new light on the coronavirus's behavior, particularly its ability to remain attached under various mechanical stresses and the implications for person-to-person transmission.

29 Nov 2023

Coffee and COVID: Study finds coffee inhibits SARS-CoV-2, offers new dietary defense strategy

Study discovers that coffee, especially its bioactive compounds like chlorogenic acids, can inhibit SARS-CoV-2 entry and reduce ACE2 and TMPRSS2 levels, indicating that coffee intake might be a potential dietary strategy for COVID-19 prevention.

16 Nov 2023

Open-science triumph: Crowdsourced initiative yields potent SARS-CoV-2 antivirals

In this study, researchers harnessed crowdsourcing and open science to develop new antivirals against SARS-CoV-2, focusing on its main protease, Mpro. Their approach led to the discovery of potent compounds, including one with high efficacy in cell lines and cross-reactivity against various COVID-19 variants, demonstrating the potential of collaborative and transparent drug discovery in tackling global health crises.

12 Nov 2023

Mucosal vaccine shows lasting defense against SARS-CoV-2 Omicron in primate study

In this groundbreaking study, researchers developed a mucosal adenoviral-vector vaccine, ChAd-SARS-CoV-2-S, which demonstrated sustained and robust immunity against a challenging Omicron variant in nonhuman primates, indicating a promising direction for durable COVID-19 protection strategies. Unlike traditional intramuscular vaccines, this mucosal vaccine elicited a comprehensive immune response, potentially paving the way for more effective and long-lasting COVID-19 vaccines.

9 Nov 2023

Omicron variant BA.2.86 spreads faster, but current antivirals hold the line

Researchers discover the BA.2.86 Omicron lineage with higher transmission potential than current dominant strains, yet show that existing antivirals remain effective. Despite its higher infectivity, BA.2.86 exhibits lower pathogenicity in hamsters, indicating decreased replication capacity may lead to less severe infections.

7 Nov 2023

New gene editing method creates first mice with human-like COVID-19

Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature.

1 Nov 2023

NF-κB activation during COVID-19 and its impact on patients with hypertension

Researchers review the role of NF-κB activation in the replication of SARS-CoV-2 and the impact of COVID-19 medications on NF-κB activation.

25 Oct 2023

BA.2.86 Omicron sub-variant shows high receptor affinity but moderate neutralization resistance

Study investigates the receptor affinity and antigenicity of the SARS-CoV-2 Omicron BA.2.86 variant, revealing that it does not show higher resistance to neutralization by human sera than other recent variants. Despite its high number of mutations and receptor affinity, the variant is slightly more sensitive to neutralization than the EG.5.1 variant, warranting continued surveillance.

24 Oct 2023

Community immunity: Steering the evolutionary course of SARS-CoV-2

Researchers in Germany have developed a comprehensive fitness model that forecasts the evolution of SARS-CoV-2 by integrating genetic, epidemiological, and immunological data. The study emphasizes the role of population immunity in shaping viral mutations and provides valuable insights into the emergence of new variants.

24 Oct 2023

Engineered bacteria could offer new treatment for hypertension

Scientists at The University of Toledo have proven that engineered bacteria can lower blood pressure, a finding that opens new doors in the pursuit of harnessing our body's own microbiome to treat hypertension.

24 Oct 2023

Is COVID-19 a risk factor for Alzheimer's disease?

The study explores the interconnected risks between COVID-19 and Alzheimer's Disease (AD), highlighting how SARS-CoV-2 can aggravate AD pathology through neuroinflammation and neurodegeneration. It raises significant concerns about the long-term cognitive implications of COVID-19, especially among those already at risk for AD.

23 Oct 2023

COVID-19 tied to elevated risk of benign prostatic hyperplasia complications

SARS-CoV-2 infection linked to increased benign prostatic hyperplasia (BPH) complications and medication use. Urological manifestations in COVID-19 patients emphasize the importance of awareness among clinicians.

22 Oct 2023

Canine transmission models provide insights into the neurological impacts of COVID-19 on human brains

The histopathologic alteration caused by SARS‑CoV‑2 on mammalian neurological systems.

20 Oct 2023

Low serotonin levels observed in long COVID and other viral infections

Researchers identify a pathophysiological mechanism linking serotonin reduction to the multifaceted etiology of post-acute sequelae of COVID-19.

20 Oct 2023

Green, matcha, and black tea: Effective weapons against Omicron subvariants, research reveals

The efficacy of tea and its catechins in deactivating the Omicron subvariant.

5 Oct 2023

Aerosolized ACE2 neutralizes COVID-19 variants in lab and mice tests

Researchers from the University of Texas Southwestern have developed an aerosolized, mutated form of ACE2 that effectively neutralizes various SARS-CoV-2 variants in both cell cultures and mice. The study suggests that this modified ACE2 has promising preventive and therapeutic potential against COVID-19, especially with its easy aerosolized administration.

28 Sep 2023

The power of nanobodies: How they impact COVID-19 immune response

The structures of 340 antibodies (Abs) and 83 nanobodies.

25 Sep 2023

How well do current vaccines hold up against new SARS-CoV-2 variants BA.2.86 and FLip?

The study explores the efficacy of three-dose monovalent or bivalent vaccinations in neutralizing newly emerged SARS-CoV-2 variants BA.2.86 and FLip. While BA.2.86 showed lower immune evasion abilities compared to recent XBB variants, it was less effectively neutralized by the monoclonal antibody S309, raising questions about vaccine efficacy against evolving strains.

17 Sep 2023

Unlocking the power of lectins: BOA emerges as a potent weapon against all SARS-CoV-2 variants

Researchers discover that antiviral lectins like BOA can effectively inhibit SARS-CoV-2 and its variants by targeting spike glycans, opening doors for potential pan-coronavirus treatments. The study reveals that BOA's multivalent interactions make it a potent inhibitor against a range of viral variants, offering promise for future therapeutic strategies.

14 Sep 2023

ACE2 News and Research

Omicron infection linked to brain structure changes in men, study finds

Collaborative study focuses on understanding the strength of adhesion of COVID-19 variants

Coffee and COVID: Study finds coffee inhibits SARS-CoV-2, offers new dietary defense strategy

Open-science triumph: Crowdsourced initiative yields potent SARS-CoV-2 antivirals

Mucosal vaccine shows lasting defense against SARS-CoV-2 Omicron in primate study

Omicron variant BA.2.86 spreads faster, but current antivirals hold the line

New gene editing method creates first mice with human-like COVID-19

NF-κB activation during COVID-19 and its impact on patients with hypertension

BA.2.86 Omicron sub-variant shows high receptor affinity but moderate neutralization resistance

Community immunity: Steering the evolutionary course of SARS-CoV-2

Engineered bacteria could offer new treatment for hypertension

Is COVID-19 a risk factor for Alzheimer's disease?

COVID-19 tied to elevated risk of benign prostatic hyperplasia complications

Canine transmission models provide insights into the neurological impacts of COVID-19 on human brains

Low serotonin levels observed in long COVID and other viral infections

Green, matcha, and black tea: Effective weapons against Omicron subvariants, research reveals

Aerosolized ACE2 neutralizes COVID-19 variants in lab and mice tests

The power of nanobodies: How they impact COVID-19 immune response

How well do current vaccines hold up against new SARS-CoV-2 variants BA.2.86 and FLip?

Unlocking the power of lectins: BOA emerges as a potent weapon against all SARS-CoV-2 variants

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News